DOCSLIB.ORG

Fenobam: a Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive Mglu5 Receptor Antagonist with Inverse Agonist Activity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fenobam: a Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive Mglu5 Receptor Antagonist with Inverse Agonist Activity 0022-3565/05/3152-711–721$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 315, No. 2 Copyright © 2005 by The American Society for Pharmacology and Experimental Therapeutics 89839/3054932 JPET 315:711–721, 2005 Printed in U.S.A. Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity Richard H. P. Porter, Georg Jaeschke, Will Spooren, Theresa M. Ballard, Bernd Bu¨ttelmann, Sabine Kolczewski, Jens-Uwe Peters, Eric Prinssen, Ju¨rgen Wichmann, Eric Vieira, Andreas Mu¨hlemann, Silvia Gatti, Vincent Mutel,1 and Pari Malherbe Pharma Division, Discovery Research CNS (R.H.P.P., W.S., T.M.B., A.M., E.P., A.M., S.G., V.M., P.M.) and Chemistry (G.J., B.B., S.K., J.-U.P., J.W., E.V.), F. Hoffmann-La Roche, Basel, Switzerland Downloaded from Received May 19, 2005; accepted July 19, 2005 ABSTRACT Ј Ϯ 3 Fenobam [N-(3-chlorophenyl)-N -(4,5-dihydro-1-methyl-4-oxo- 31 4 nM, respectively. MPEP inhibited [ H]fenobam binding jpet.aspetjournals.org Ϯ 1H-imidazole-2-yl)urea] is an atypical anxiolytic agent with un- to human mGlu5 receptors with a Ki value of 6.7 0.7 nM, known molecular target that has previously been demonstrated indicating a common binding site shared by both allosteric both in rodents and human to exert anxiolytic activity. Here, we antagonists. Fenobam exhibits anxiolytic activity in the stress- report that fenobam is a selective and potent metabotropic induced hyperthermia model, Vogel conflict test, Geller-Seifter glutamate (mGlu)5 receptor antagonist acting at an allosteric conflict test, and conditioned emotional response with a mini- modulatory site shared with 2-methyl-6-phenylethynyl-pyridine mum effective dose of 10 to 30 mg/kg p.o. Furthermore, feno- (MPEP), the protypical selective mGlu5 receptor antagonist. bam is devoid of GABAergic activity, confirming previous re- Fenobam inhibited quisqualate-evoked intracellular calcium re- ports that fenobam acts by a mechanism distinct from at ASPET Journals on January 24, 2020 ϭ Ϯ sponse mediated by human mGlu5 receptor with IC50 58 benzodiazepines. The non-GABAergic activity of fenobam, 2 nM. It acted in a noncompetitive manner, similar to MPEP and coupled with its robust anxiolytic activity and reported efficacy demonstrated inverse agonist properties, blocking 66% of the in human in a double blind placebo-controlled trial, supports mGlu5 receptor basal activity (in an over expressed cell line) the potential of developing mGlu5 receptor antagonists with an ϭ Ϯ 3 with an IC50 84 13 nM. [ H]Fenobam bound to rat and improved therapeutic window over benzodiazepines as novel Ϯ human recombinant receptors with Kd values of 54 6 and anxiolytic agents. Anxiety disorders are the most common mental illnesses in agents, especially for short term use, but they suffer from dose- the Western world. Although effective treatment exists in the limiting side effects, including sedation, memory impairment, form of the benzodiazepines and SSRI/norepinephrine reuptake ataxia, abuse potential, an interaction with ethanol, and phys- inhibitors, there is still considerable room for improvement. The ical dependence (Woods et al., 1992). The SSRIs/norepinephrine benzodiazepines are generally regarded as the most efficacious reuptake inhibitor as well as other serotonergic agents (such as buspirone) are commonly prescribed for the longer term treat- 1 Current address: Addex Pharmaceuticals S.A., Plan Les Ouates, ment of anxiety but in addition to a delayed onset of action of 3 Switzerland. to 6 weeks and sometimes an increased level of agitation for the Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. first few weeks, they also suffer from side effects in terms of doi:10.1124/jpet.105.089839. sexual dysfunction, nausea, anorexia, and headache (Vaswani ABBREVIATIONS: SSRI, serotonin reuptake inhibitor; mGlu, metabotropic glutamate; GPCR, G protein-coupled receptor; TM, transmembrane; MPEP, 2-methyl-6-(phenylethynyl)-pyridine; HTS, high-throughput screening; FLIPR, fluorometric imaging plate reader; fenobam, N-(3-chloro- phenyl)-NЈ-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea; MTEP, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pridine; SIB-1757, 6-methyl-2-(phe- nylazo)-3-pyridinol); SIB-1893, (E)-2-methyl-6-(2-phenylethenyl)pyridine; NPS 2390, N-adamantan-1-yl-2-quinoxaline-carboxamide-2-quinoxa- line-carboxamide-N-adamantan-1-yl; S-4-CPG, S-4-carboxyphenylglycine; HEK, human embryonic kidney; PBS, phosphate-buffered saline; RT, 2ϩ ␥ room temperature; IP, inositol phosphates; hGlu, human metabotropic glutamate; [Ca ]i, intracellular calcium; DMSO, dimethyl sulfoxide; GTP S, guanosine 5Ј-O-(3-thio)triphosphate; S-4C3HPG, S-4-carboxy-3-hydrophenylglycine; S-DHPG, S-dihydrophenylglycine; S-3HPG, 3-hydroxyphe- nylglycine; 2Me4CPG, 2-methyl-4-carboxyphenylglycine; -4-CPG, S-4-carboxyphenylglycine; (ϩ)-MCPG, (ϩ)-␣-methyl-4-carboxyphenylglycine; CHPG, RS-2-chloro-5-hydroxyphenylglycine; L-AP4, 2-amino-4-phsophonobutyric acid; CHO, Chinese hamster ovary; RIA, radioimmunoassay; CER, conditioned emotional response; SR, suppression ratio; ANOVA, analysis of variance; PG, phenylglycine; MED, minimum effective dose. 711 712 Porter et al. et al., 2003). Numerous recent preclinical and clinical studies tionally, fenobam has been reported to be active in outpa- have demonstrated the involvement of metabotropic glutamate tients with severe anxiety (Pecknold et al., 1980) and in a (mGlu) receptors in the anxiety and stress disorders (Swanson single blind study (Lapierre and Oyewumi, 1982). In all three et al., 2005). studies, fenobam was reported to have a good safety profile The mGlu5 receptor is one of eight G protein-coupled recep- and no oversedation, no muscle relaxant, and no interaction tors (GPCRs) activated by glutamate, in addition to the well with ethanol, further supporting a mechanism of action that characterized ionotropic glutamate receptors (Conn and Pin, is distinct from GABA-ergic potentiation (Pecknold et al., 1997). The eight mGlu receptors are divided into three groups 1980, 1982; Lapierre and Oyewumi, 1982). However, feno- on the basis of their sequence similarities, signal transduction, bam has also been reported to be inactive in one phase II and agonist rank order of potency. Group I (mGlu1 and 5) are outpatient trial where side effects of a psychostimulant na- coupled to the activation of phospholipase C, and group II ture were reported (Friedmann et al., 1980). At the time, (mGlu2 and 3) and group III (mGlu4, 6, 7, and 8) are negatively fenobam was discontinued from further development as an coupled to cAMP production (Conn and Pin, 1997). The mGlu anxiolytic, with indications that the molecule required fur- receptors are members of class C family of GPCRs, having a ther refinement (Friedmann et al., 1980; Wu et al., 1995). large extracellular amino-terminal domain for agonist binding Given the recent interest in mGlu5 receptors for anxiety (venus flytrap model) (Kunishima et al., 2000) and the 7TM and our recent discovery of fenobam’s mode of action via helical segments that form a binding pocket for the novel class mGlu5 receptor antagonism, we have characterized fenobam of compounds acting as allosteric modulators (Kew, 2004). Be- Downloaded from in a broad range of in vitro pharmacology tests and in vivo cause mGlu5 receptors are highly expressed in brain regions rodent models of anxiety. In the present study, we show that known to be involved in emotional processes such as the limbic fenobam is a potent, subtype-selective, and noncompetitive brain structures (prefrontal cortex, amygdala, basal ganglia, antagonist of mGlu5 receptors and that fenobam has inverse and hippocampal regions) (Shigemoto et al., 1993; Romano et agonist activity similar to MPEP (Pagano et al., 2000). Fur- al., 1995), the mGlu5 receptors have attracted considerable thermore, we demonstrate that fenobam has potent antianx- attention for psychiatric disorders (Spooren et al., 2001). In- jpet.aspetjournals.org deed, with the notable exception of the benzodiazepines, the iety properties in rodent models of anxiety tests, including prototypical noncompetitive antagonist MPEP (Gasparini et al., stress-induced hyperthermia, Vogel conflict, Geller-Seifter 1999) and its close analog MTEP (Cosford et al., 2003) (Fig. 1) conflict, and conditioned emotional response. have been reported to be active in the broadest range of pre- clinical anxiety tests, confirming a critical involvement of this receptor in mood control. Materials and Methods During a functional high-throughput screening (HTS) cam- at ASPET Journals on January 24, 2020 Materials paign (fluorometric imaging plate reader; FLIPR) of F. Hoff- mann-La Roche’s small-molecule library for mGlu5 modula- Fenobam and MTEP were synthesized at F. Hoffmann-La Roche tors, we identified fenobam as a potent antagonist of mGlu5 (Basel, Switzerland). SIB-1757, SIB-1893, 7-hydroxyiminocyclopro- pan[b]chromen-1a-carboxylic acid ethyl ester, and NPS 2390 are receptors. Interestingly, fenobam (McN-3377) was originally 3 developed as a nonbenzodiazepine anxiolytic (by McNeil Lab- commercially available. [ H]Fenobam (specific activity, 24.6 Ci/ mmol) was synthesized by Dr. P. Huguenin (Hoffmann-La Roche oratories, 1978–1982), with an unknown molecular target. In chemical and isotope laboratories). MPEP (specific activity, 36 Ci/ preclinical studies, fenobam is reported to be active in rat mmol; TRK 1070), L-quisqualic acid (0188), and S-4-CPG (0323) were models of anxiety (conflict tasks including Geller-Seifter and obtained from Tocris Cookson Inc. (Bristol, UK). MPEP was obtained Vogel) (Patel et al., 1982), and this activity was not blocked from Sigma (Buchs, Switzerland). myo-[2-3H]Inositol (TRK 911) and by a benzodiazepine antagonist (Goldberg et al., 1983). yttrium silicate RNA binding beads (RPNQ0013) were purchased In a double blind placebo-controlled clinical trial, fenobam from GE Healthcare (Little Chalfont, Buckinghamshire, UK). Glu- had an efficacy and onset of action comparable with diaze- tamate pyruvate transaminase (catalog number 737 127) was from pam (HAM-A/HSRC/HAM-D) (Pecknold et al., 1982).
Load more

Recommended publications
  • Selective Blockade of the Metabotropic Glutamate Receptor Mglur5 Protects Mouse Livers in in Vitro and Ex Vivo Models of Ischemia Reperfusion Injury
    International Journal of Molecular Sciences Article Selective Blockade of the Metabotropic Glutamate Receptor mGluR5 Protects Mouse Livers in In Vitro and Ex Vivo Models of Ischemia Reperfusion Injury Andrea Ferrigno 1,* ID , Clarissa Berardo 1, Laura Giuseppina Di Pasqua 1, Veronica Siciliano 1, Plinio Richelmi 1, Ferdinando Nicoletti 2,3 and Mariapia Vairetti 1 ID 1 Department of Internal Medicine and Therapeutics, Cellular and Molecular Pharmacology and Toxicology Unit, University of Pavia, 27100 Pavia, Italy; [email protected] (C.B.); [email protected] (L.G.D.P.); [email protected] (V.S.); [email protected] (P.R.); [email protected] (M.V.) 2 Department of Physiology and Pharmacology, Sapienza University, 00185 Roma, Italy; [email protected] 3 I.R.C.C.S. Neuromed, 86077 Pozzilli, Italy * Correspondence: [email protected]; Tel.: +39-0382-986451 Received: 20 November 2017; Accepted: 22 January 2018; Published: 23 January 2018 Abstract: 2-Methyl-6-(phenylethynyl)pyridine (MPEP), a negative allosteric modulator of the metabotropic glutamate receptor (mGluR) 5, protects hepatocytes from ischemic injury. In astrocytes and microglia, MPEP depletes ATP. These findings seem to be self-contradictory, since ATP depletion is a fundamental stressor in ischemia. This study attempted to reconstruct the mechanism of MPEP-mediated ATP depletion and the consequences of ATP depletion on protection against ischemic injury. We compared the effects of MPEP and other mGluR5 negative modulators on ATP concentration when measured in rat hepatocytes and acellular solutions. We also evaluated the effects of mGluR5 blockade on viability in rat hepatocytes exposed to hypoxia. Furthermore, we studied the effects of MPEP treatment on mouse livers subjected to cold ischemia and warm ischemia reperfusion.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • Dynamic L-Glutamate Signaling in the Prefrontal Cortex and the Effects of Methylphenidate Treatment
    University of Kentucky UKnowledge Theses and Dissertations--Neuroscience Neuroscience 2012 DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT Catherine Elizabeth Mattinson University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Mattinson, Catherine Elizabeth, "DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT" (2012). Theses and Dissertations--Neuroscience. 4. https://uknowledge.uky.edu/neurobio_etds/4 This Doctoral Dissertation is brought to you for free and open access by the Neuroscience at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Neuroscience by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
    [Show full text]
  • The Effect of Intrahippocampal Injection of Group II and III Metobotropic Glutamate Receptor Agonists on Anxiety; the Role of Neuropeptide Y
    Neuropsychopharmacology (2007) 32, 1242–1250 & 2007 Nature Publishing Group All rights reserved 0893-133X/07 $30.00 www.neuropsychopharmacology.org The Effect of Intrahippocampal Injection of Group II and III Metobotropic Glutamate Receptor Agonists on Anxiety; the Role of Neuropeptide Y ´ ,1 1 1 1 Maria Smiałowska* , Joanna M Wieron´ska , Helena Domin and Barbara Zie˛ba 1Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krako´w, Poland Earlier studies conducted by our group and by other authors indicated that metabotropic glutamatergic receptor (mGluR) ligands might have anxiolytic activity and that amygdalar neuropeptide Y (NPY) neurons were engaged in that effect. Apart from the amygdala, the hippocampus, another limbic structure, also seems to be engaged in regulation of anxiety. It is rich in mGluRs and contains numerous NPY interneurons. In the present study, we investigated the anxiolytic activity of group II and III mGluR agonists after injection into the hippocampus, and attempted to establish whether hippocampal NPY neurons and receptors were engaged in the observed effects. Male Wistar rats were bilaterally microinjected with the group II mGluR agonist (2S,10S,20S)-2-(carboxycyclopropyl)glycine (L-CCG-I), group III mGluR agonist O-Phospho-L-serine (L-SOP), NPY, the Y1 receptor antagonist BIBO 3304, and the Y2 receptor antagonist BIIE 0246 into the CA1 or dentate area (DG). The effect of those compounds on anxiety was tested in the elevated plus-maze. Moreover, the effects of L-CCG-I and L-SOP on the expression of NPYmRNA in the hippocampus were studied using in situ hybridization method. It was found that a significant anxiolytic effect was induced by L-SOP injection into the CA1 region or by L-CCG-I injection into the DG.
    [Show full text]
  • Acamprosate in the Treatment of Binge Eating Disorder: a Placebo-Controlled Trial
    CE ACTIVITY Acamprosate in the Treatment of Binge Eating Disorder: A Placebo-Controlled Trial Susan L. McElroy, MD1* ABSTRACT obsessive-compulsiveness of binge eat- 1 Objective: To assess preliminarily the ing, food craving, and quality of life. Anna I. Guerdjikova, PhD effectiveness of acamprosate in binge Among completers, weight and BMI 1 Erin L. Winstanley, PhD eating disorder (BED). decreased slightly in the acamprosate 1 group but increased in the placebo Anne M. O’Melia, MD Method: In this 10-week, randomized, 1 group. Nicole Mori, CNP placebo-controlled, flexible dose trial, 40 1 Jessica McCoy, BA outpatients with BED received acampro- Discussion: Although acamprosate did Paul E. Keck Jr., MD1 sate (N 5 20) or placebo (N 5 20). The not separate from placebo on any out- James I. Hudson, MD, ScD2 primary outcome measure was binge eat- come variable in the longitudinal analy- ing episode frequency. sis, results of the endpoint and completer analyses suggest the drug may have Results: While acamprosate was not some utility in BED. VC 2010 by Wiley associated with a significantly greater Periodicals, Inc. rate of reduction in binge eating episode frequency or any other measure in the Keywords: acamprosate; binge eating primary longitudinal analysis, in the end- disorder; obesity; glutamate point analysis it was associated with stat- istically significant improvements in binge day frequency and measures of (Int J Eat Disord 2011; 44:81–90) Introduction The treatment of BED remains a challenge.5 Cogni- tive behavioral and interpersonal therapies and selec- Binge eating disorder (BED), characterized by recur- tive serotonin-reuptake inhibitor (SSRI) antidepres- rent binge-eating episodes without inappropriate sants are effective for reducing binge eating, but usu- 1 compensatory weight loss behaviors, is an impor- ally are not associated with clinically significant tant public health problem.
    [Show full text]
  • 1 Activation of the Same Mglur5 Receptors in the Amygdala Causes Divergent Effects 2 on Specific Versus Indiscriminate Fear 3
    1 Activation of the same mGluR5 receptors in the amygdala causes divergent effects 2 on specific versus indiscriminate fear 3 4 Mohammed Mostafizur Rahman1,2,#, Sonal Kedia1,#, Giselle Fernandes1#, Sumantra 5 Chattarji1,2,3* 6 7 1National Centre for Biological Sciences, Tata Institute of Fundamental Research, 8 Bangalore 560065, India 9 10 2Centre for Brain Development and Repair, Institute for Stem Cell Biology and 11 Regenerative Medicine, Bangalore 560065, India 12 13 3Centre for Integrative Physiology, Deanery of Biomedical Sciences, University of 14 Edinburgh, Hugh Robson Building, George Square, Edinburgh EH89XD, UK 15 16 17 * Corresponding Author: Prof. Sumantra Chattarji 18 Centre for Brain Development and Repair, Institute for 19 Stem Cell Biology and Regenerative Medicine and 20 National Centre for Biological Sciences 21 Bangalore 560065, INDIA 22 E-Mail: [email protected] 23 # Equal contribution 24 1 25 Abstract 26 27 Although mGluR5-antagonists prevent fear and anxiety, little is known about how the 28 same receptor in the amygdala gives rise to both. Combining in vitro and in vivo 29 activation of mGluR5 in rats, we identify specific changes in intrinsic excitability and 30 synaptic plasticity in basolateral amygdala neurons that give rise to temporally distinct 31 and mutually exclusive effects on fear-related behaviors. The immediate impact of 32 mGluR5 activation is to produce anxiety manifested as indiscriminate fear of both tone 33 and context. Surprisingly, this state does not interfere with the proper encoding of tone- 34 shock associations that eventually lead to enhanced cue-specific fear. These results 35 provide a new framework for dissecting the functional impact of amygdalar mGluR- 36 plasticity on fear versus anxiety in health and disease.
    [Show full text]
  • Identification and Analysis of Hepatitis C Virus NS3 Helicase Inhibitors Using Nucleic Acid Binding Assays Sourav Mukherjee1, Alicia M
    Published online 27 June 2012 Nucleic Acids Research, 2012, Vol. 40, No. 17 8607–8621 doi:10.1093/nar/gks623 Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays Sourav Mukherjee1, Alicia M. Hanson1, William R. Shadrick1, Jean Ndjomou1, Noreena L. Sweeney1, John J. Hernandez1, Diana Bartczak1, Kelin Li2, Kevin J. Frankowski2, Julie A. Heck3, Leggy A. Arnold1, Frank J. Schoenen2 and David N. Frick1,* 1Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, 2University of Kansas Specialized Chemistry Center, University of Kansas, 2034 Becker Dr., Lawrence, KS 66047 and 3Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA Received March 26, 2012; Revised May 30, 2012; Accepted June 4, 2012 Downloaded from ABSTRACT INTRODUCTION Typical assays used to discover and analyze small All cells and viruses need helicases to read, replicate and molecules that inhibit the hepatitis C virus (HCV) repair their genomes. Cellular organisms encode NS3 helicase yield few hits and are often con- numerous specialized helicases that unwind DNA, RNA http://nar.oxfordjournals.org/ founded by compound interference. Oligonucleotide or displace nucleic acid binding proteins in reactions binding assays are examined here as an alternative. fuelled by ATP hydrolysis. Small molecules that inhibit After comparing fluorescence polarization (FP), helicases would therefore be valuable as molecular homogeneous time-resolved fluorescence (HTRFÕ; probes to understand the biological role of a particular Cisbio) and AlphaScreenÕ (Perkin Elmer) assays, helicase, or as antibiotic or antiviral drugs (1,2). For an FP-based assay was chosen to screen Sigma’s example, several compounds that inhibit a helicase Library of Pharmacologically Active Compounds encoded by herpes simplex virus (HSV) are potent drugs in animal models (3,4).
    [Show full text]
  • Structural Studies of the Interaction Between Mglu5 And
    STRUCTURAL STUDIES OF THE INTERACTION BETWEEN MGLU5 AND ALLOSTERIC MODULATORS By Elizabeth Dong Nguyen Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Chemical and Physical Biology August, 2013 Nashville, Tennessee Approved: Professor Walter J. Chazin Professor P. Jeffrey Conn Professor Terry P. Lybrand Professor David L. Tabb Copyright © 2013 by Elizabeth Dong Nguyen All Rights Reserved ACKNOWLEDGEMENTS The work presented here was made possible by Public Health Service award T32 GM07347 from the National Institute of General Medical Studies for the Vanderbilt Medical-Scientist Training Program (MSTP), the Paul Calabresi Medical Student Research Fellowship from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation and a Deutscher Akademischer Austausch Dienst (DAAD) research grant from the German Academic Exchange Service. Computational resources were provided by the Advanced Computing Center for Research and Education and the Center for Structural Biology at Vanderbilt University. I would like to thank my advisor, Dr. Jens Meiler, who fostered in me the desire to pursue research as a summer undergraduate student and continued to support, guide and mentor me through my graduate studies. His excitement for science is infectious and has inspired my own ambitions to spread the passion of science to others. I would like to thank other faculty members who aided in my scientific growth while at Vanderbilt University, particularly my committee members: Dr. Walter Chazin, Dr. Jeff Conn, Dr. Terry Lybrand and Dr. David Tabb. They have continually provided guidance and encouragement for my research progress and career development.
    [Show full text]
  • Addiction Research Tools
    Addiction Research Tools Cayman offers a wide range of products to study targeted brain circuits mediating the behavioral effects of drugs of abuse. We also offer over 2,000 high-quality analytical standards that have been synthesized using a range of analytical techniques to verify identity, purity, and other relevant characteristics. Whether you are looking to quickly identify or quantify drugs of abuse via mass spec or understand their physiological and toxicological properties, Cayman has the right tools to help make your research possible. DopamineDopamine transportertransporters s DopamineDopamine Drugs Drugs DopamineDopamine receptorresceptors Drugs of Abuse Amphetamines and Other Stimulants Benzodiazepines Item No. Product Name Item No. Product Name 15650 D-Amphetamine (hydrochloride) (exempt preparation) 15287 α-hydroxy Alprazolam 10488 Bupropion (hydrochloride) 14263 Clonazepam 15655 (–)-(S)-Cathinone (hydrochloride) (exempt preparation) 18173 Clonazolam 22165 Cocaine (hydrochloride) 15554 Diclazepam 11159 Dimethocaine (hydrochloride) 15889 Estazolam 11630 Ketamine (hydrochloride) 24481 Flualprazolam 13971 3,4-MDMA (hydrochloride) 11449 Ketazolam 15657 Mephedrone (hydrochloride) (exempt preparation) 15891 Lorazepam 15656 Methcathinone (hydrochloride) (exempt preparation) 16193 Midazolam 14276 PCP (hydrochloride) 22577 Triazolam Over 650 amphetamine and other stimulant standards available online Over 100 benzodiazepine standards available online Addiction Research Products are available in BULK quantities to qualified institutions
    [Show full text]
  • Hayward Et Al, 2016
    Pharmacology & Therapeutics 158 (2016) 41–51 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: F. Tarazi Low attentive and high impulsive rats: A translational animal model of ADHD and disorders of attention and impulse control Andrew Hayward a,⁎, Anneka Tomlinson b, Joanna C. Neill a,⁎ a Manchester Pharmacy School, University of Manchester, Manchester M13 9PT, UK b Green Templeton College, University of Oxford, Oxford OX2 6HG, UK article info abstract Available online 23 November 2015 Many human conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia and drug abuse are characterised by deficits in attention and impulse control. Carefully validated animal models are required to Keywords: enhance our understanding of the pathophysiology of these disorders, enabling development of improved phar- Animal model macotherapy. Recent models have attempted to recreate the psychopathology of these conditions using chemical ADHD lesions or genetic manipulations. In a diverse population, where the aetiology is not fully understood and is 5C-SRTT multifactorial, these methods are restricted in their ability to identify novel targets for drug discovery. Two 5C-CPT tasks of visual attention and impulsive action typically used in rodents and based on the human continuous High Performance Low Performance performance task (CPT) include, the well-established 5 choice serial reaction time task (5C-SRTT) and the more recently validated, 5 choice continuous performance task (5C-CPT) which provides enhanced translational value. We suggest that separating animals by behavioural performance into high and low attentive and impulsivity cohorts using established parameters in these tasks offers a model with enhanced translational value.
    [Show full text]
  • Dysregulated Nitric Oxide Signaling As a Candidate Mechanism of Fragile X Syndrome and Other Neuropsychiatric Disorders
    REVIEW ARTICLE published: 22 July 2014 doi: 10.3389/fgene.2014.00239 Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders Steven M. Colvin and Kenneth Y. Kwan* Department of Human Genetics – The Molecular and Behavioral Neuroscience Institute, University of Michigan Medical School, Ann Arbor, MI, USA Edited by: A mechanistic understanding of the pathophysiology underpinning psychiatric disorders is Peter Kennedy Todd, University of essential for the development of targeted molecular therapies. For fragile X syndrome Michigan, USA (FXS), recent mechanistic studies have been focused on the metabotropic glutamate Reviewed by: receptor (mGluR) signaling pathway. This line of research has led to the discovery Maria Paola Lombardi, University of Amsterdam, Netherlands of promising candidate drugs currently undergoing various phases of clinical trial, and Rhiannon Meredith, VU University represents a model of how biological insights can inform therapeutic strategies in Amsterdam, Netherlands neurodevelopmental disorders. Although mGluR signaling is a key mechanism at which Christina Gross, Cincinnati Children’s Hospital Medical Center, USA targeted treatments can be directed, it is likely to be one of many mechanisms contributing to FXS. A more complete understanding of the molecular and neural underpinnings of the *Correspondence: Kenneth Y. Kwan, Department of disorder is expected to inform additional therapeutic strategies. Alterations in the assembly Human Genetics – The Molecular and of neural circuits in the neocortex have been recently implicated in genetic studies of autism Behavioral Neuroscience Institute, and schizophrenia, and may also contribute to FXS. In this review, we explore dysregulated University of Michigan Medical School, 5041 BSRB, 109 Zina Pitcher nitric oxide signaling in the developing neocortex as a novel candidate mechanism of Place, Ann Arbor, MI 48109-2200, FXS.
    [Show full text]
  • Optical Control of Pain in Vivo with a Photoactive Mglu5 Receptor
    RESEARCH ARTICLE Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator Joan Font1,2,3†, Marc Lo´ pez-Cano4,5†, Serena Notartomaso6, Pamela Scarselli6, Paola Di Pietro6, Roger Bresolı´-Obach7, Giuseppe Battaglia6, Fanny Malhaire8, Xavier Rovira8, Juanlo Catena1, Jesu´s Giraldo2,3,9, Jean-Philippe Pin8, Vı´ctorFerna´ ndez-Duen˜ as4,5, Cyril Goudet8, Santi Nonell7, Ferdinando Nicoletti6,10, Amadeu Llebaria1*, Francisco Ciruela4,5* 1MCS, Laboratory of Medicinal Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain; 2Institut de Neurocie`ncies, Universitat Auto`noma de Barcelona, Bellaterra, Spain; 3Unitat de Bioestadı´stica, Universitat Auto`noma de Barcelona, Bellaterra, Spain; 4Departament de Patologia i Terape`utica Experimental, Facultat de Medicina i Cie`ncies de la Salut, IDIBELL, Universitat de Barcelona, Barcelona, Spain; 5Institut de Neurocie`ncies, Universitat de Barcelona, Barcelona, Spain; 6I.R.C.C.S. Neuromed, Pozzilli, Italy; 7Institut Quı´mic de Sarria`, Universitat Ramon Llull, Barcelona, Spain; 8IGF, CNRS, INSERM, Univ. Montpellier, Montpellier, France; 9Network Biomedical Research Center on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; 10Department of Physiology and Pharmacology, University Sapienza, Rome, Italy *For correspondence: amadeu. Abstract Light-operated drugs constitute a major target in drug discovery, since they may [email protected] (AL); provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP- [email protected] (FC) 26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor †These authors contributed negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a equally to this work photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons.
    [Show full text]